Oncotarget

Research Papers:

Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth

Julin Shuxian Wong, Emma Warbrick, Borek Vojtesk, Jeffrey Hill and David Philip Lane _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2013; 4:1019-1036. https://doi.org/10.18632/oncotarget.1075

Metrics: PDF 1528 views  |   HTML 1940 views  |   ?  


Abstract

Julin S. Wong1,2 Emma Warbrick2, Borek Vojtesk3, Jeffrey Hill4 and David P. Lane1

1 p53 Laboratory, 8A Biomedical Grove, Immunos #06-06, Singapore, Singapore.

2 Epithelial Genetics Group, Medical Sciences Institute, College of Life Sciences and Medicine, Dentistry & Nursing, Dundee, Scotland, UK.

3 Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.

4 Experimental Therapeutics Centre, 31 Biopolis Way, Nanos Level 3, Singapore.

Correspondence:

David P. Lane, email:

Keywords: c-Met, seeMet 2, monoclonal antibody, temperature sensitive & cryptic epitope

Received: June 4, 2013 Accepted: June 27, 2013 Published: June 29, 2013

Abstract

c-Met is a tyrosine receptor kinase which is activated by its ligand, the hepatocyte growth factor. Activation of c-Met leads to a wide spectrum of biological activities such as motility, angiogenesis, morphogenesis, cell survival and cell regeneration. c-Met is abnormally activated in many tumour types. Aberrant c-Met activation was found to induce tumour development, tumour cell migration and invasion, and the worst and final step in cancer progression, metastasis. In addition, c-Met activation in cells was also shown to confer resistance to apoptosis induced by UV damage or chemotherapeutic drugs. This study describes the development of monoclonal antibodies against c-Met as therapeutic molecules in cancer treatment/diagnostics. A panel of c-Met monoclonal antibodies was developed and characterised by epitope mapping, Western blotting, immunoprecipitation, agonist/antagonist effect in cell scatter assays and for their ability to recognise native c-Met by flow cytometry. We refer to these antibodies as Specifically Engaging Extracellular c-Met (seeMet). seeMet 2 and 13 bound strongly to native c-Met in flow cytometry and reduced SNU-5 cell growth. Interestingly, seeMet 2 binding was strongly reduced at 4oC when compared to 37oC. Detail mapping of the seeMet 2 epitope indicated a cryptic binding site hidden within the c-Met α-chain.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1075